Recent research from France highlights a concerning link between GLP1 agonists and an increased risk of thyroid cancer in patients with type 2 diabetes. The findings suggest a 50 to 75% higher risk after one to three years of using these drugs. This discussion challenges previous assumptions about the safety of GLP1 treatments, emphasizing the need for further scrutiny and understanding of their long-term effects.
